TeamDrive
RUS

Partners

Team Drive is engaged in managing two large active projects under cooperation between the Russian investment corporation RUSNANO which is currently implementing the national policy on the development of high-tech sectors and Domain Associates LLC., a leading US-based venture capital firm with an exclusive focus on life sciences. In March 2012 the partners announced the signing of an agreement to be subject to investments in innovative medical technologies.

To perform this task a subsidiary RMI Partners, a company specializing in managing pharmaceutical and medical projects, has been established by Team Drive.


RUSNANO

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. 

Read more..


 Domain Associates LLC

American company Domain Associates LLC was founded in 1985 and is one of the most recognized management companies of venture funds specializing in life sciences projects. Over 260 projects have been created and financed in the course of its existence.

Read more..

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more